Chronic heart failure Circulatory System Heart failure
Conditions
Interventions
Randomisation will be by blocks using an unequal block size.
Control group ? 10 patients with hypertension or coronary artery disease but not heart failure. The control group does not
Sponsors
Hull and East Yorkshire Hospitals NHS Trust (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Male and female, 18 y.o. plus, legally able to provide written informed consent 2. Clinical diagnosis of Heart Failure 3. Objective evidence of cardiac dysfunction 3.1. NTproBNP >200ng/L and at least one of the following: 3.2. Left ventricular ejection fraction (=45%) 3.3. Left atrial dimension >40mm 4. Treated with at least 40mg/day of furosemide or 1mg/day of bumetanide 5. Receiving other guideline indicated therapy for heart failure 6. Patients should be in sinus rhythm. Atrial fibrillation may reduce accuracy of some signals
Exclusion criteria
Exclusion criteria: 1. Patients with implanted pacemakers or defibrillators 2. Severe aortic or mitral valve disease 3. Breathlessness at rest or on minor exertion 4. Chest pain at rest or on mild or moderate exertion 5. Patients with unstable heart failure or 'brittle' diabetes 6. Patients who are known to be intolerant [including patients using Phosphodiesterase type 5 (PDEV) inhibitors] of nitrates or hydralazine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| No single primary outcome. This is a pilot study to investigate the ability of novel noninvasive sensors to detect and track the acute haemodynamic effects of medication (hydralazine and/or hydralazine or combination) and a series of physiological manoueuvres. | — |
Secondary
| Measure | Time frame |
|---|---|
| No secondary outcome measures | — |
Countries
United Kingdom
Outcome results
None listed